Speqta: Strategic Review Completed

Research Note



Redeye retains its positive view on Speqta following the Strategic Review. We believe the significant cash dividend combined with investments in Bidbrain is a balanced low-risk approach that should satisfy most shareholders.


Fredrik Nilsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.